Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 7/20 | 0.47 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | LTB4R2 | Q9NPC1 | 5/20 | 0.38 |
| ▸ | OXTR | P30559 | 1/20 | 0.38 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 2/20 | 0.38 |
| ▸ | KDM4A | O75164 | 1/20 | 0.38 |
| ▸ | KDM5C | P41229 | 1/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.38 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.37 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.37 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.37 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.36 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2034 | 1.00 | AGTR1 (0.47) | AGTR1MMEFFAR1AKR1B1LTB4R2 | |
| SCHEMBL2980 | 0.93 | AGTR1 (0.42) | AGTR1MMEFFAR1AKR1B1LTB4R2 | |
| SCHEMBL2918 | 0.90 | AGTR1 (0.40) | AGTR1MMEFFAR1AKR1B1LTB4R2 | |
| SCHEMBL2630 | 0.90 | AGTR1 (0.40) | AGTR1MMEFFAR1AKR1B1LTB4R2 | |
| SCHEMBL14998792 | 0.90 | AGTR1 (0.44) | AGTR1MMEFFAR1AKR1B1OXTR | |
| SCHEMBL2141 | 0.90 | FFAR1 (0.43) | AGTR1MMEFFAR1AKR1B1LTB4R2 | |
| SCHEMBL2443439 | 0.89 | LTB4R2 (0.44) | AGTR1MMEFFAR1AKR1B1LTB4R2 | |
| SCHEMBL8476144 | 0.89 | AGTR1 (0.40) | AGTR1LTB4R2KDM5A | |
| SCHEMBL2032 | 0.84 | AGTR1 (0.66) | AGTR1MMEFFAR1AKR1B1LTB4R2 | |
| SCHEMBL2033 | 0.84 | AGTR1 (0.66) | AGTR1MMEFFAR1AKR1B1LTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7659406-B2 | Process for preparing valsartan | DR. REDDY'S LABORATORIES LIMITED (IN) | 2010-02-09 | — | — | US | claimed |
| US-20060149079-A1 | Process for preparing valsartan | DR. REDDY'S LABORATORIES, INC. | 2006-07-06 | — | — | US | claimed |
| EP-4037679-B1 | A PROCESS FOR THE PREPARATION OF HIGHLY PURE VALSARTAN | HARMAN FINOCHEM LTD (IN) | 2025-08-06 | — | — | EP | disclosed |
| US-12365654-B2 | Process for the preparation of highly pure valsartan | HARMAN FINOCHEM LIMITED (IN) | 2025-07-22 | — | — | US | disclosed |
| US-20230057675-A1 | A PROCESS FOR THE PREPARATION OF HIGHLY PURE VALSARTAN | HARMAN FINOCHEM LIMITED (IN) | 2023-02-23 | — | — | US | disclosed |
| CN-110078640-B | Synthesis method of valsartan intermediate | 浙江美诺华药物化学有限公司 | 2022-04-05 | — | — | CN | disclosed |
| WO-2021111464-A1 | A PROCESS FOR THE PREPARATION OF HIGHLY PURE VALSARTAN | HARMAN FINOCHEM LIMITED (IN) | 2021-06-10 | — | — | WO | disclosed |
| US-8492577-B2 | Process for preparation of valsartan intermediate | HETERO RESEARCH FOUNDATION (IN) | 2013-07-23 | — | — | US | disclosed |
| WO-2012056294-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF N-PENTANOYL-N-[[2'-(1H-TETRAZOL-5-YI)[1,1'-BIPHENYL]-4-YI]METHYL]-L-VALINE | JUBILANT LIFE SCIENCES LTD. (IN) | 2012-05-03 | — | — | WO | disclosed |
| US-20110237822-A1 | PROCESS FOR PREPARATION OF VALSARTAN INTERMEDIATE | HETERO RESEARCH FOUNDATION (IN) | 2011-09-29 | — | — | US | disclosed |
| US-7923567-B2 | Process for preparing valsartan | ALEMBIC LIMITED (IN) | 2011-04-12 | — | — | US | disclosed |
| US-7361770-B2 | Process for preparation of valsartan | HETERO DRUGS LIMITED (IN) | 2008-04-22 | — | — | US | disclosed |
| WO-2007032019-A2 | PROCESS FOR PREPARING VALSARTAN | ALEMBIC LIMITED (IN) | 2007-03-22 | — | — | WO | disclosed |
| US-20060258878-A1 | chemical intermediate organic acid salt of N-[(2'-cyanobiphenyl-4-yl)methyl]-(L)-valine ester for hypotensive agents; treating anxiety, glaucoma and cardiovascular disorders | ALEMBIC LIMITED (IN) | 2006-11-16 | — | — | US | disclosed |
| US-20060149079-A1 | Process for preparing valsartan | DR. REDDY'S LABORATORIES, INC. | 2006-07-06 | — | — | US | disclosed |
| US-20060100443-A1 | Novel process for preparation of valsartan | HETERO DRUGS LIMITED (IN) | 2006-05-11 | — | — | US | disclosed |
| WO-2004111018-A1 | A NOVEL PROCESS FOR PREPARATION OF VALSARTAN | HETERO DRUGS LIMITED (IN) | 2004-12-23 | — | — | WO | disclosed |
| US-20040072886-A1 | Novel crystalline forms of (S)-N- (1-Carboxy-2-methyl-prop-1-yl) -N-pentanoyl-N- [2' -(1H-tetrazol-5-yl)- biphenyl-4-yl methyl] amine (Valsartan) | DR. REDDY'S LABORATORIES LIMITED | 2004-04-15 | — | — | US | disclosed |
| US-5965592-A | HYPOTENSIVE AGENTS | NOVARTIS CORPORATION (US) | 1999-10-12 | — | — | US | disclosed |
| US-5399578-A | Hypotensive; valsartan; high blood pressure and cardiac insufficiency | CIBA-GEIGY CORP (US) | 1995-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230057675-A1 | A PROCESS FOR THE PREPARATION OF HIGHLY PURE VALSARTAN | REN, AGT, ACE | AGTR1 4/4885MME 6/4885FFAR1 2908/4885 |
| US-12365654-B2 | Process for the preparation of highly pure valsartan | REN, AGT, ACE | AGTR1 4/4885MME 5/4885FFAR1 2478/4885 |
| US-20060258878-A1 | chemical intermediate organic acid salt of N-[(2'-cyanobiphenyl-4-yl)methyl]-(L)-valine ester for hypotensive agents; treating anxiety, glaucoma and cardiovascular disorders | AGTR1, AGTR2, AGT | AGTR1 1/4885MME 233/4885FFAR1 1011/4885 |
| US-20040072886-A1 | Novel crystalline forms of (S)-N- (1-Carboxy-2-methyl-prop-1-yl) -N-pentanoyl-N- [2' -(1H-tetrazol-5-yl)- biphenyl-4-yl methyl] amine (Valsartan) | REN, AGTR1, TTR | AGTR1 2/4885MME 16/4885FFAR1 210/4885 |
| US-20110237822-A1 | PROCESS FOR PREPARATION OF VALSARTAN INTERMEDIATE | REN, AGT, ACE | AGTR1 6/4885MME 11/4885FFAR1 2643/4885 |
| US-20060149079-A1 | Process for preparing valsartan | PREP, TMPRSS15, REN | AGTR1 14/4885MME 19/4885FFAR1 2124/4885 |
| US-20060100443-A1 | Novel process for preparation of valsartan | ACE, REN, AGT | AGTR1 11/4885MME 10/4885FFAR1 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.